Clinical Trial

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Study acronym: DESTINY-Lung06
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.
Protocol Amendment History 4 changes
notable Trial sites expanded: 160 -> 237 locations 2026-07-22
notable Trial sites expanded: 100 -> 160 locations 2026-07-03
notable Primary completion pushed: 2030-03-05 -> 2030-04-24 2026-07-03
minor Completion pushed: 2032-07-05 -> 2032-11-24 2026-07-03
Trial Details
NCT Number NCT06899126
Lead Sponsor Daiichi Sankyo
Collaborators: Merck Sharp & Dohme LLC
Conditions Non-small Cell Lung Cancer
Enrollment 686 participants
Start Date 2025-10-24
Primary Completion 2030-04-24 (estimated)
Study Completion 2032-11-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-21